About: Hydroxychloroquine Safety Outcome within Approved Therapeutic Protocol for COVID-19 Outpatients in Saudi Arabia

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Hydroxychloroquine Safety Outcome within Approved Therapeutic Protocol for COVID-19 Outpatients in Saudi Arabia Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Hydroxychloroquine Safety Outcome within Approved Therapeutic Protocol for COVID-19 Outpatients in Saudi Arabia
Creator	Alrabiah, Fahad Abdulkareem, Khaled Abogazalah, Fouad Alenazi, Eissa Alfaifi, Amel Alghofaili, Fahad Alkhalifah, Nasser Almohaizeie, Abdullah Elkady, Ehab Hassanein, Mustafa Jokdar, Hani Mahmoud, Nagla Mohana, Abdulrhman Radwan, Nashwa Sulaiman, Tarek
Source	MedRxiv
abstract	Background: Healthcare systems globally has been challenged following the COVID-19 pandemic, since late 2019. Multiple approaches and strategies have been performed to relieve the pressure and support existing healthcare systems. The Saudi Arabian Ministry of Health (MOH) launched an initiative to support the National Healthcare System. Since the 5th of June 2020, 238 outpatient fever clinics were established across Saudi Arabia. Methods: A cross-sectional study included 2,733 eligible patients subjected to MOH treatment protocol (hydroxychloroquine and zinc) and revisited the clinics within 3-7 days after treatment initiation. This study aimed to assess the safety outcome and reported adverse events from hydroxychloroquine use among suspected COVID-19 patients. The data was collected through an electronic link and cross-checked with that of the national database (Health Electronic Surveillance Network, HESN) and reports from the MOH Morbidity and Mortality (M&M) Committee. Results: Majority of the cases were males (70.4%). Upon reassessing the studied participants within 3-7 days, 240 patients (8.8%) discontinued the treatment protocol because of the development of side effects (4.1%) and for non-clinical reasons in the remaining (4.7%). Medication side effects overall were reported among (6.7%) of all studied participants, including mainly cardiovascular adverse events (2.5%), followed by gastrointestinal (GI) symptoms (2.4%). No Intensive Care Unit (ICU) admission or death were reported among these patients. Conclusion: In our study, results show that the use of hydroxychloroquine for COVID-19 patients in mild to moderate cases in an outpatient setting, within the protocol recommendation and inclusion/exclusion criteria, is safe, highly tolerable, and with minimum side effects.
has issue date	2020-08-17(xsd:dateTime)
bibo:doi	10.1101/2020.08.16.20175752
has license	medrxiv
sha1sum (hex)	6f1c3dad48cf27ac39642e6d79fe9704626a9ec7
schema:url	https://doi.org/10.1101/2020.08.16.20175752
resource representing a document's title	Hydroxychloroquine Safety Outcome within Approved Therapeutic Protocol for COVID-19 Outpatients in Saudi Arabia
resource representing a document's body	covid:6f1c3dad48cf27ac39642e6d79fe9704626a9ec7#body_text
is schema:about of	named entity 'Healthcare' named entity 'support' named entity 'June' named entity 'FEVER' named entity '2019' named entity 'ESTABLISHED' named entity 'MULTIPLE' named entity 'PROTOCOL' named entity 'COVID' named entity 'initiative' named entity 'Health' named entity 'treatment protocol' named entity 'myalgia' named entity 'fatality rate' named entity 'hydroxychloroquine' named entity 'fever' named entity 'COVID' named entity 'peer review' named entity 'hydroxychloroquine' named entity 'safety profile' named entity 'treatment protocol' named entity 'World Health Organisation' named entity 'hydroxychloroquine' named entity 'fever' named entity 'fever' named entity 'lactating' named entity 'morbidity' named entity 'COVID' named entity 'COVID-19' named entity 'G6PD deficiency' named entity 'sore throat' named entity 'diarrhoea' named entity 'medRxiv' named entity 'treatment protocol' named entity 'sample size' named entity 'ICU' named entity 'Saudi Arabian Ministry of Health' named entity 'PCR' named entity 'hydroxychloroquine' named entity 'diarrhoea' named entity 'hydroxychloroquine' named entity 'azithromycin' named entity 'abdominal pain' named entity '95% CI' named entity 'peer review' named entity 'peer review' named entity 'runny nose' named entity 'COVID' named entity 'COVID' named entity 'adverse events' named entity 'adverse events' named entity 'treatment protocol' named entity 'adverse events' named entity 'zinc sulphate' named entity 'SARS-CoV-2' named entity 'hydroxychloroquine' named entity 'adverse effects' named entity '3, 4' named entity 'COVID' named entity 'non-clinical' named entity 'QT prolongation' named entity 'PCR' named entity 'health records' named entity 'adverse effects' named entity 'ECG' named entity 'treatment protocol' named entity 'vomiting' named entity 'hydroxychloroquine' named entity 'non-clinical' named entity 'chloroquine' named entity 'hydroxychloroquine'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software